CERS
CERS clinical trials: CERUS CORP
Every trial on ClinicalTrials.gov where CERUS CORP is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 24
- Trials linked
- 17
- As lead sponsor
- 7
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CERS on the catalyst calendar · CERS registry changes
- Primary completion Jul 2028Sponsor estimateNo phase registeredNCT07218185Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated HemorrhageCerus Corporation · HypofibrinogenemiaEnrolling by invitationCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2030Sponsor estimatePhase 2NCT07152379Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to...Cerus Corporation · Transfusion Reaction, HemolyticNot yet recruitingCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2026ActualPhase 3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation · AnemiaCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026Sponsor estimatePhase 2NCT07155031Biotin-Acridine Red Cell Exchange KineticsCerus Corporation · Sickle Cell DiseaseWithdrawnCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2NCT07015437A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1Cerus Corporation · Healthy SubjectsRecruitingCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2023ActualPhase 3NCT03459287Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery PatientsCerus Corporation · AnemiaCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2025ActualPhase 2NCT06697223A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for...Cerus Corporation · Healthy SubjectsCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 16, 2021ActualPhase 2NCT04022889In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100%...Cerus Corporation · HealthyCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2020ActualNo phase registeredNCT02549222A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet ComponentsCerus Corporation · Transfusion Related Acute Lung InjuryCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2020ActualPhase 1NCT02295501A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of...Cerus Corporation · Acute Ebola Virus DiseaseTerminatedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 21, 2017ActualPhase 3NCT01740531Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC...Cerus Corporation · Thalassemia MajorCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 2NCT02653443A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo StudyCerus Corporation · HealthyTerminatedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualNo phase registeredNCT02305732A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet ComponentsCerus Corporation · Chikungunya VirusCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 2NCT02310412A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored...Cerus Corporation · HealthyCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 2NCT01711346A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood CellsCerus Corporation · Focus: Assess Post Infusion Viability of S303 RBCsCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 3NCT01716923Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute AnemiaCerus Corporation · Focus:Use of S303 RBCs in Patients With Acute AnemiaCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2009ActualPhase 3NCT00261924Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven DaysCerus Corporation · ThrombocytopeniaCompletedCERSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025ActualPhase 1NCT04426591Biotin-RBC Transfusion in SCDMarianne Yee · Sickle Cell DiseaseCompletedCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2024ActualPhase 4NCT05711524Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative BleedingWeill Medical College of Cornell University · HypofibrinogenemiaCompletedCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2024ActualPhase 4NCT04681638Plasma Resuscitation Without Lung InjuryCoalition for National Trauma Research · BurnsTerminatedCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2024Sponsor estimateNo phase registeredNCT04020224INTERCEPT Safety Evaluation on Whole BloodSwiss Transfusion SRC · Safety IssuesWithdrawnCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2020Sponsor estimateNo phase registeredNCT03486054INTERCEPT Safety Evaluation in Anemic PatientsSwiss Transfusion SRC · AnemiaWithdrawnCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2019Sponsor estimateNo phase registeredNCT03384407Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood UnitsUniversity of Cincinnati · Red Cell Survival in Healthy VolunteersUnknown statusCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2014ActualPhase 3NCT01642563Italian Platelet Technology Assessment StudyCentro Nazionale Sangue · LeukemiaTerminatedCERSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 24 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner